The U.S. Food and Drug Administration has approved the use of Kalydeco® (ivacaftor) for infants with cystic fibrosis as young as four months who have certain mutations.
Site Search
On Mar. 11, the Cystic Fibrosis Foundation presented the Alex, Jena and Dream Big Awards to leaders in the CF community for their dedication to the Foundation's mission of finding a cure.
Ginger Birnbaum and Mike Beatty lead efforts in Dallas for banner conference -- "teamMATEs for a Cure.”
Choate Construction's National Corporate Team raised over $670,000 for the Cystic Fibrosis Foundation in 2019, serving as a role model for corporations looking to integrate philanthropy into their business model.
On the heels of exciting progress in the fight against CF, more than 500 of the Cystic Fibrosis Foundation's most dedicated volunteers, chapter staff and corporate supporters came together at the 12th annual CF Volunteer Leadership Conference, and hundreds more watched via live stream March 20-21.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.
Leaders of the Cystic Fibrosis Foundation and dedicated volunteers from the CF community came together last week around a shared commitment to not stop working until a cure is found for every person living with cystic fibrosis.
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.